KnowledgeBase

• Home
• Antimicrobials
• Microorganisms
• About Us
• Contact Us

• Search All
• Search by Antimicrobial
• Search by Microorganism
• 

Home › Search by Microorganism › Candida parapsilosis (P92 + planktonic)

• Candida parapsilosis
• Candida parapsilosis (00-629)
• Candida parapsilosis (1997)
• Candida parapsilosis (1998)
• Candida parapsilosis (1999)
• Candida parapsilosis (24h)
• Candida parapsilosis (48h)
• Candida parapsilosis (ATCC 10232)
• Candida parapsilosis (ATCC 20019)
• Candida parapsilosis (ATCC 220129)
• Candida parapsilosis (ATCC 22013)
• Candida parapsilosis (ATCC 22018)
• Candida parapsilosis (ATCC 22019)
• Candida parapsilosis (ATCC 27853)
• Candida parapsilosis (ATCC 7330)
• Candida parapsilosis (ATCC 90018)
• Candida parapsilosis (B1089)
• Candida parapsilosis (B1153)
• Candida parapsilosis (B3421)
• Candida parapsilosis (B392)
• Candida parapsilosis (BR-A25)
• Candida parapsilosis (BR-A26)
• Candida parapsilosis (BR-A27)
• Candida parapsilosis (BR-A28)
• Candida parapsilosis (BR-A29)
• Candida parapsilosis (BR-A30)
• Candida parapsilosis (BR-A31)
• Candida parapsilosis (C276)
• Candida parapsilosis (CBS 604)
• Candida parapsilosis (clinical isolate)
• Candida parapsilosis (esophageal candidiasis isolate)
• Candida parapsilosis (fluconazole-resistant)
• Candida parapsilosis (fluconazole-susceptible)
• Candida parapsilosis (H4)
• Candida parapsilosis (H5)
• Candida parapsilosis (H6)
• Candida parapsilosis (IFM 5747)
• Candida parapsilosis (IFM 5804)
• Candida parapsilosis (invasive candidiasis isolate)
• Candida parapsilosis (Israel)
• Candida parapsilosis (KCCM 50271)
• Candida parapsilosis (method : M27-A2-AM3 + 24h)
• Candida parapsilosis (method : M27-A2-AM3 + 48h)
• Candida parapsilosis (method : SYO + 24h)
• Candida parapsilosis (method : SYO + 48h)
• Candida parapsilosis (NBRC 1396)
• Candida parapsilosis (NCPF 3104)
• Candida parapsilosis (P/A71 + planktonic)
• Candida parapsilosis (P/A71)
• Candida parapsilosis (P92 + planktonic)
• Candida parapsilosis (P92)
• Candida parapsilosis (patient isolate)

This project is supported by TOKU-E which specializes in manufacturing ultra-pure antibiotics for a broad spectrum of biotechnology applications as well as for the pharmaceutical industry. TOKU-E is a global leader in biotechnology innovation, offering great benefits and applications to the biopharmaceutical and diagnostic industries as well as for biotechnology research communities.
Privacy Policy | Terms of Use
Knowledgebase version 1.8